Determining the effect of doxycycline in the treatment of asthma_like infections compared with classical treatment
Design
Clinical trial, double-blind, randomized, phase 2_3 on 50 patients. The randomized site was used for randomization.
Settings and conduct
pulmonary subspecialty clinic
Participants/Inclusion and exclusion criteria
Patient over 18 years with new infection with asthma-like symptoms for more than 6 weeks Cough, shortness of breath, stimulation with environmental factors and obstructive spirometry with reversibility of more than 12% with short-acting beta-agonist
Intervention groups
Patient over 18 years with new infection with asthma-like symptoms for more than 6 weeks Cough, shortness of breath, stimulation with environmental factors and obstructive spirometry with reversibility of more than 12% with short-acting beta-agonist
Main outcome variables
Wheezing at the physical examination
Asthma attacks
Recurrence of asthma
Cough
Dyspnea
General information
Reason for update
Acronym
IRCT registration information
IRCT registration number:IRCT20220412054507N1
Registration date:2022-04-18, 1401/01/29
Registration timing:retrospective
Last update:2022-04-18, 1401/01/29
Update count:0
Registration date
2022-04-18, 1401/01/29
Registrant information
Name
Sara Nejati Zahmatkesh
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 51 3878 9652
Email address
sarah.nejati.z@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2021-04-12, 1400/01/23
Expected recruitment end date
2022-02-12, 1400/11/23
Actual recruitment start date
2021-04-21, 1400/02/01
Actual recruitment end date
2022-01-21, 1400/11/01
Trial completion date
empty
Scientific title
Evaluation of the effect of doxycycline on asthma_like infection
Public title
effect of doxycycline on asthma_like infection
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Patient older than 18 years with new infection with asthma-like symptoms and signs for more than 6 weeks like cough,dyspnea,stimulation with environmental factors and obstructive spirometry with reversibility of more than 12% with short-acting beta-agonist
Exclusion criteria:
Pregnancy/GERD/Sensivity to Doxycycline/ Liver diseases
Age
From 18 years old
Gender
Both
Phase
2-3
Groups that have been masked
Participant
Care provider
Investigator
Outcome assessor
Sample size
Target sample size:
50
Actual sample size reached:
52
Randomization (investigator's opinion)
Randomized
Randomization description
Using https://www.randomizer.org, we randomly assign 50 codes to two groups of doxycycline and placebo. The drugs are all in the form of capsules with the same shape, size, color and packaging but different codes. Medications are given to a co-worker who is in our clinic and is unaware of the type of medication or placebo and the disease.
Blinding (investigator's opinion)
Double blinded
Blinding description
Medications are given to a co-worker who is in our clinic and is unaware of the type of medication or placebo and the disease, so that patients can be given a package of medication.
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics Committee in Research, Islamic Azad University, Mashhad